Insights Widest with the analysis, Proactive gives perspectives that others don't.

Challenge trials can speed up vaccine development hVIVO to merge with Open Orphan to boost scale

The challenge trial charts the entire disease life cycle from healthy to sick and back to health.

23 hours, 25 minutes ago
Deep dive

Open Orphan recruits hVIVO for its rare disease mission

Open Orphan reversed into Venn Life Sciences in June 2019

23 hours, 53 minutes ago
Deep dive

Summit Therapeutics well placed in the race to find next-generation antibiotic

Summit Therapeutics' potential breakthrough targets C.difficile

1 day, 21 hours ago
Deep dive

C4X Discovery well-funded and confident on deal flow

"We have eleven programmes, of which three three are relatively near term for licensing," said...

1 day, 22 hours ago

What the UK election result could mean for companies and markets

With the result of the 12 December election still uncertain, the three most likely results could...

1 day, 23 hours ago


hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

20 hours, 21 minutes ago

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest to the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.